+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Design of PEGylated soluble tumor necrosis factor receptor type I for chronic inflammatory diseases



Design of PEGylated soluble tumor necrosis factor receptor type I for chronic inflammatory diseases



Advanced Drug Delivery Reviews 55(10): 1315-1336, 26 September




Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 034700569

Download citation: RISBibTeXText


Related references

Design of PEGylated soluble tumor necrosis factor receptor type I (PEG sTNF-RI) for chronic inflammatory diseases. Advanced Drug Delivery Reviews 55(10): 1315-1336, 2003

PEGylated recombinant human soluble tumour necrosis factor receptor type I (r-Hu-sTNF-RI): novel high affinity TNF receptor designed for chronic inflammatory diseases. Annals of the Rheumatic Diseases 58 Suppl 1: I73-I81, 1999

Soluble tumor necrosis factor receptor type I A novel therapeutic designed for chronic inflammatory diseases. Annals of the Rheumatic Diseases 58(SUPPL 1): I73-I81, 1999

Non-immunogenicity of a pegylated soluble tumor necrosis factor receptor type I. Arthritis & Rheumatism 42(9 SUPPL ): S77, Sept, 1999

Novel erythropoiesis stimulating protein enhances pegylated soluble tumor necrosis factor receptor type 1 alleviation of anemia of chronic disease in a rodent model of systemic inflammation. Blood 98(11 Part 1): 7a, November 16, 2001

A phase 1 study of pegylated soluble tumor necrosis factor receptor type 1 in subjects with rheumatoid arthritis. Arthritis & Rheumatism 42(9 SUPPL ): S236, Sept, 1999

Effects of PEGylated soluble tumor necrosis factor receptor type I (PEG sTNF-RI) alone and in combination with methotrexate in adjuvant arthritic rats. Clinical and Experimental Rheumatology 17(5): 553-560, 1999

Combination benefit of treatment with the cytokine inhibitors interleukin-1 receptor antagonist and PEGylated soluble tumor necrosis factor receptor type I in animal models of rheumatoid arthritis. Arthritis and Rheumatism 43(12): 2648-2659, 2001

Combination benefit of PEGylated soluble tumor necrosis factor receptor type I (PEG sTNF-RI) and dexamethasone or indomethacin in adjuvant arthritic rats. Inflammation Research 48(8): 453-460, 1999

Analysis of tumor necrosis factor-alpha, interleukin-6, interleukin-1beta, soluble tumor necrosis factor receptors I and II, interleukin-6 soluble receptor, interleukin-1 soluble receptor type II, interleukin-1 receptor antagonist, and protein in the synovial fluid of patients with temporomandibular joint disorders. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics 99(3): 276-284, 2005

The pharmacokinetics of subcutaneous injections of pegylated recombinant methionyl human soluble tumor necrosis factor- type I receptor in subjects with active rheumatoid arthritis. Arthritis & Rheumatism 42(9 SUPPL ): S79, Sept, 1999

Development of a baculovirus expression system for soluble porcine tumor necrosis factor receptor type I and soluble porcine tumor necrosis factor receptor type I-IgG fusion protein. Veterinary Immunology and Immunopathology 86(3/4): 251-254, 2002

Treatment with pegylated recombinant methionyl human soluble tumor necrosis factor-type 1 receptor prevents development of Sjogrens syndrome and diabetes in the NOD mouse model. Arthritis & Rheumatism 42(9 SUPPL ): S403, Sept, 1999